Stock Watch: Lilly’s Emgality Trod A Well-Beaten Path To Clinical Failure

Beware The Clinical Trial Comparator Arm

The outcome of any clinical study is uncertain but the choice of active comparator and sometimes even the placebo arm can magnify unpredictability. Emgality’s recent head-to-head failure in migraine is just the latest in a long list of casualties.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Stock Watch

More from Business